My next question is for Mr. Keon and Ms. Cox.
Do producers of generic drugs account for most of Canada’s pharmaceutical manufacturing capacity?
Would CETA’s intellectual property provisions likely lead to greater development or manufacturing of brand-name drugs in Canada?